{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T15:52:04Z","timestamp":1783698724932,"version":"3.55.0"},"posted":{"date-parts":[[2026,2,28]]},"group-title":"Physiology","reference-count":58,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"NIH","award":["R01DK133930"],"award-info":[{"award-number":["R01DK133930"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:p>\n                  Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), are strongly linked to cardiac dysfunction, particularly, heart failure with preserved ejection fraction (HFpEF), yet the mechanisms underlying this association remain unclear because robust integrative preclinical models are lacking and the liver and heart are rarely studied as a coordinated system. Here we show that\n                  <jats:italic>\n                    Alms1\n                    <jats:sup>-\/-<\/jats:sup>\n                  <\/jats:italic>\n                  (Foz\/Foz) mice fed a Western diet develop MASH with advanced liver fibrosis accompanied by a HFpEF-like phenotype characterized by left ventricular hypertrophy, impaired cardiomyocyte contractility, reduced \u03b2-adrenergic reserve, elevated BNP, and increased mortality despite ejection fraction &gt;50%. Liver fibrosis emerged as a parameter strongly associated with the cardiac dysfunction. Remarkably, dietary reversal improved hepatic architecture, normalized cardiac function, and improved survival, revealing marked plasticity of the liver-heart axis. Analyses of left ventricular (LV) remodeling revealed mitochondrial dysfunction, altered substrate utilization, and extracellular matrix remodeling in the LV, with consistent concordance to human HFpEF transcriptomic signatures. Ultrastructural studies confirmed mitochondrial injury and sarcomeric disorganization, linking metabolic failure to impaired cardiomyocyte performance. Together, these findings identify mitochondrial dysfunction as an important feature of MASLD-associated HFpEF-like cardiac dysfunction and establish the Foz\/Foz model as a powerful platform for investigating pathophysiological pathways linking metabolic liver disease to cardiac dysfunction and for testing mechanism-based therapeutic strategies.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>STRUCTURED ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction associated steatotic liver disease (MASLD) and its advanced form, MASH, are closely linked to cardiac dysfunction, particularly heart failure with preserved ejection fraction (HFpEF). However, the mechanisms underlying MASLD-associated HFpEF and its reversibility remain poorly understood, largely due to the lack of robust preclinical models. Here, we established a translational model of MASLD-associated cardiac dysfunction that recapitulates the key features of human HFpEF. We applied functional and transcriptomic analyses of the left ventricle (LV) to define the pathways associated with cardiac dysfunction and its reversibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      <jats:italic>\n                        Alms1\n                        <jats:sup>-\/-<\/jats:sup>\n                      <\/jats:italic>\n                      (Foz\/Foz) mice and wild-type littermates were fed normal chow (NC) or Western diet (WD) for up to 36 weeks (wk). Reversibility was modeled by switching WD-fed Foz\/Foz mice at 12wk back to NC for 12wk. Cardiac assessment included echocardiography, invasive hemodynamics with dobutamine stimulation, histopathology, electron microscopy and isolated cardiomyocyte contractility. LV transcriptomes were profiled by bulk RNA sequencing and analyzed by differential expression and pathway enrichment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Foz\/Foz mice on WD for 24wk developed metabolic syndrome and MASH with advanced liver fibrosis. Cardiac phenotyping showed LV hypertrophy, impaired cardiomyocyte contractility, reduced \u03b2-adrenergic reserve, elevated plasma BNP, and increased mortality while the ejection fraction was preserved (&gt;50%), consistent with HFpEF. The progression of cardiac dysfunction was closely associated with liver fibrosis that developed during MASH. Switching WD-fed Foz\/Foz mice at 12wk to normal chow diet reversed hepatic fibrosis, restored LV function, and reduced mortality, demonstrating plasticity of the liver-heart axis. LV transcriptomic analysis revealed that cardiac impairment in these mice was associated with mitochondrial dysfunction, altered substrate utilization, extracellular matrix remodeling, and metabolic stress; pathways that are similarly dysregulated in human HFpEF. Cardiac electron microscopy revealed swollen mitochondria with disrupted cristae, which improved following dietary intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mitochondrial dysfunction and fibroinflammatory remodeling are prominent features of MASLD-associated cardiac dysfunction. Reversal of hepatic and cardiac phenotypes with dietary intervention, together with elucidation of underlying pathways, establish the Foz\/Foz model as a useful translational platform for studying liver-heart axis in MASLD.<\/jats:p>\n                    <jats:fig id=\"ufig1\" position=\"float\" orientation=\"portrait\" fig-type=\"figure\">\n                      <jats:graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"708088v2_ufig1\" position=\"float\" orientation=\"portrait\"\/>\n                    <\/jats:fig>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.26.708088","type":"posted-content","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T19:10:13Z","timestamp":1772305813000},"source":"Crossref","is-referenced-by-count":1,"title":["A Translational Model of MASLD-Associated HFpEF Defines Mitochondrial Dysfunction and Cardiac Plasticity During Disease Progression and Regression"],"prefix":"10.64898","author":[{"given":"Souradipta","family":"Ganguly","sequence":"first","affiliation":[{"name":"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA"},{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betul","family":"Gunes","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusu","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Suarez","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Gupta","sequence":"additional","affiliation":[{"name":"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Ishizuka","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Murad","sequence":"additional","affiliation":[{"name":"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Kisseleva","sequence":"additional","affiliation":[{"name":"Department of Surgery, School of Medicine, University of California, San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Dillmann","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirk","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Adler","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Brenner","sequence":"additional","affiliation":[{"name":"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA"},{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debanjan","family":"Dhar","sequence":"additional","affiliation":[{"name":"Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, USA"},{"name":"Department of Medicine, University of California, San Diego, La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026060603451896000_2026.02.26.708088v2.1","doi-asserted-by":"crossref","unstructured":"Eskridge W , Cryer DR , Schattenberg JM , Gastaldelli A , Malhi H , Allen AM , et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023;12.","DOI":"10.3390\/jcm12196216"},{"key":"2026060603451896000_2026.02.26.708088v2.2","doi-asserted-by":"crossref","first-page":"e2454707","DOI":"10.1001\/jamanetworkopen.2024.54707","article-title":"Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050","volume":"8","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026060603451896000_2026.02.26.708088v2.3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(24)00318-8","article-title":"Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment","volume":"13","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026060603451896000_2026.02.26.708088v2.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.04.015"},{"key":"2026060603451896000_2026.02.26.708088v2.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.06.018"},{"key":"2026060603451896000_2026.02.26.708088v2.6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s12072-023-10543-8","article-title":"An international multidisciplinary consensus statement on MAFLD and the risk of CVD","volume":"17","year":"2023","journal-title":"Hepatol Int"},{"key":"2026060603451896000_2026.02.26.708088v2.7","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325724"},{"key":"2026060603451896000_2026.02.26.708088v2.8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2023-330595"},{"key":"2026060603451896000_2026.02.26.708088v2.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03283-1"},{"key":"2026060603451896000_2026.02.26.708088v2.10","doi-asserted-by":"crossref","unstructured":"Braha A , Timar B , Ivan V , Balica MM , Daniluc L , Timar R . Novel Biomarkers of Grade I Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Patients with Metabolic-Dysfunction-Associated Steatotic Liver Disease. J Clin Med. 2024;13.","DOI":"10.20944\/preprints202409.1312.v1"},{"key":"2026060603451896000_2026.02.26.708088v2.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.01.049"},{"key":"2026060603451896000_2026.02.26.708088v2.12","doi-asserted-by":"crossref","unstructured":"Peng D , Yu Z , Wang M , Shi J , Sun L , Zhang Y , et al. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology. Front Endocrinol (Lausanne). 2022;13:935390.","DOI":"10.3389\/fendo.2022.935390"},{"key":"2026060603451896000_2026.02.26.708088v2.13","doi-asserted-by":"crossref","unstructured":"Brar AS , Khanna T , Sohal A , Hatwal J , Sharma V , Singh C , et al. Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review. World J Cardiol. 2026;18:111954.","DOI":"10.4330\/wjc.v18.i1.111954"},{"key":"2026060603451896000_2026.02.26.708088v2.14","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014279"},{"key":"2026060603451896000_2026.02.26.708088v2.15","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1038\/s44161-025-00754-7","article-title":"Modeling HFpEF in animals","volume":"4","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"2026060603451896000_2026.02.26.708088v2.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab389"},{"key":"2026060603451896000_2026.02.26.708088v2.17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jcmgh.2021.05.010","article-title":"Nonalcoholic Steatohepatitis and HCC in a Hyperphagic Mouse Accelerated by Western Diet","volume":"12","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2026060603451896000_2026.02.26.708088v2.18","doi-asserted-by":"crossref","unstructured":"Zeng XF , Varady KA , Wang XD , Targher G , Byrne CD , Tayyem R , et al. The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus. Metabolism. 2024;161:156028.","DOI":"10.1016\/j.metabol.2024.156028"},{"key":"2026060603451896000_2026.02.26.708088v2.19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2405746121"},{"key":"2026060603451896000_2026.02.26.708088v2.20","doi-asserted-by":"publisher","DOI":"10.1159\/000508636"},{"key":"2026060603451896000_2026.02.26.708088v2.21","doi-asserted-by":"publisher","DOI":"10.1210\/me.2005-0494"},{"key":"2026060603451896000_2026.02.26.708088v2.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.01.022"},{"key":"2026060603451896000_2026.02.26.708088v2.23","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4346"},{"key":"2026060603451896000_2026.02.26.708088v2.24","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000102042.83024.CA"},{"key":"2026060603451896000_2026.02.26.708088v2.25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300308"},{"key":"2026060603451896000_2026.02.26.708088v2.26","first-page":"I82","article-title":"Beta-adrenergic inotropic responsiveness of patients with heart failure: studies with intracoronary dobutamine infusion","volume":"61","year":"1987","journal-title":"Circ Res"},{"key":"2026060603451896000_2026.02.26.708088v2.27","first-page":"e27969","article-title":"Cirrhotic Cardiomyopathy: The Interplay Between Liver and Heart","volume":"14","year":"2022","journal-title":"Cureus"},{"key":"2026060603451896000_2026.02.26.708088v2.28","doi-asserted-by":"crossref","unstructured":"Liu H , Nguyen HH , Yoon KT , Lee SS . Pathogenic Mechanisms Underlying Cirrhotic Cardiomyopathy. Front Netw Physiol. 2022;2:849253.","DOI":"10.3389\/fnetp.2022.849253"},{"key":"2026060603451896000_2026.02.26.708088v2.29","first-page":"1893","article-title":"The role of BNP testing in heart failure","volume":"74","year":"2006","journal-title":"Am Fam Physician"},{"key":"2026060603451896000_2026.02.26.708088v2.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-024-01067-1"},{"key":"2026060603451896000_2026.02.26.708088v2.31","doi-asserted-by":"crossref","unstructured":"Inacio JM , Cristo F , Pinheiro M , Vasques-Novoa F , Saraiva F , Nunes MM , et al. Myocardial RNA Sequencing Reveals New Potential Therapeutic Targets in Heart Failure with Preserved Ejection Fraction. Biomedicines. 2023;11.","DOI":"10.3390\/biomedicines11082131"},{"key":"2026060603451896000_2026.02.26.708088v2.32","doi-asserted-by":"crossref","unstructured":"Bernhard J , Galli L , Speidl WS , Krychtiuk KA . Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis. Curr Cardiol Rep. 2025;27:28.","DOI":"10.1007\/s11886-024-02185-5"},{"key":"2026060603451896000_2026.02.26.708088v2.33","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15530"},{"key":"2026060603451896000_2026.02.26.708088v2.34","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.009625"},{"key":"2026060603451896000_2026.02.26.708088v2.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2013.07.023"},{"key":"2026060603451896000_2026.02.26.708088v2.36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-5223(19)37950-4","article-title":"Ultrastructural and cytochemical correlates of myocardial protection by cardiac hypothermia in man","volume":"79","year":"1980","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026060603451896000_2026.02.26.708088v2.37","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00202.2023"},{"key":"2026060603451896000_2026.02.26.708088v2.38","doi-asserted-by":"crossref","unstructured":"Kalkhoran SB , Munro P , Qiao F , Ong SB , Hall AR , Cabrera-Fuentes H , et al. Unique morphological characteristics of mitochondrial subtypes in the heart: the effect of ischemia and ischemic preconditioning. Discoveries (Craiova). 2017;5.","DOI":"10.15190\/d.2017.1"},{"key":"2026060603451896000_2026.02.26.708088v2.39","doi-asserted-by":"crossref","unstructured":"Capone F , Haseli SP , Liu L , Strocchi S , Langenberg C , Lusis AJ , et al. HFpEF and MASLD: converging mechanisms and clinical implications. Nat Rev Cardiol. 2026.","DOI":"10.1038\/s41569-026-01257-z"},{"key":"2026060603451896000_2026.02.26.708088v2.40","doi-asserted-by":"crossref","unstructured":"Briand F , Maupoint J , Brousseau E , Breyner N , Bouchet M , Costard C , et al. Elafibranor improves diet-induced nonalcoholic steatohepatitis associated with heart failure with preserved ejection fraction in Golden Syrian hamsters. Metabolism. 2021;117:154707.","DOI":"10.1016\/j.metabol.2021.154707"},{"key":"2026060603451896000_2026.02.26.708088v2.41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.5551\/jat.40956","article-title":"A High-Fat and High-Cholesterol Diet Induces Cardiac Fibrosis, Vascular Endothelial, and Left Ventricular Diastolic Dysfunction in SHRSP5\/Dmcr Rats","volume":"25","year":"2018","journal-title":"J Atheroscler Thromb"},{"key":"2026060603451896000_2026.02.26.708088v2.42","doi-asserted-by":"crossref","first-page":"e0339642","DOI":"10.1371\/journal.pone.0339642","article-title":"Diet-induced steatohepatitis does not cause heart failure with preserved ejection fraction in male middle-aged C57BL\/6N mice","volume":"20","year":"2025","journal-title":"PloS one"},{"key":"2026060603451896000_2026.02.26.708088v2.43","doi-asserted-by":"publisher","DOI":"10.1126\/science.adl4100"},{"key":"2026060603451896000_2026.02.26.708088v2.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08317-9"},{"key":"2026060603451896000_2026.02.26.708088v2.45","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.043"},{"key":"2026060603451896000_2026.02.26.708088v2.46","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis","volume":"21","year":"2023","journal-title":"Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association"},{"key":"2026060603451896000_2026.02.26.708088v2.47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp2305181"},{"key":"2026060603451896000_2026.02.26.708088v2.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1100-z"},{"key":"2026060603451896000_2026.02.26.708088v2.49","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.120.317046"},{"key":"2026060603451896000_2026.02.26.708088v2.50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061846"},{"key":"2026060603451896000_2026.02.26.708088v2.51","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.043450"},{"key":"2026060603451896000_2026.02.26.708088v2.52","doi-asserted-by":"crossref","unstructured":"Sebastiao MJ , Almeida HV , Serra M , Hamdani N , Saraiva F , Lourenco AP , et al. Unveiling Human Proteome Signatures of Heart Failure with Preserved Ejection Fraction. Biomedicines. 2022;10.","DOI":"10.3390\/biomedicines10112943"},{"key":"2026060603451896000_2026.02.26.708088v2.53","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.070535"},{"key":"2026060603451896000_2026.02.26.708088v2.54","doi-asserted-by":"crossref","unstructured":"Muzurovic E , Katsiki N , Volcansek S , Plescia F , Rizzo M , Mantzoros CS . Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond. Metabolism. 2026;177:156494.","DOI":"10.1016\/j.metabol.2026.156494"},{"key":"2026060603451896000_2026.02.26.708088v2.55","doi-asserted-by":"crossref","unstructured":"Angelidi AM , Sanoudou D , Hill MA , Mantzoros CS . Management of patients with the cardio renal liver metabolic syndrome: The need for a multidisciplinary approach in research, education and practice. Metabolism. 2024;159:155997.","DOI":"10.1016\/j.metabol.2024.155997"},{"key":"2026060603451896000_2026.02.26.708088v2.56","doi-asserted-by":"crossref","unstructured":"Zhou XD , Lazarus JV , Krittanawong C , Targher G , Byrne CD , Younossi ZM , et al. Pharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart-liver co-management. Lancet Gastroenterol Hepatol. 2026.","DOI":"10.1016\/S2468-1253(25)00323-1"},{"key":"2026060603451896000_2026.02.26.708088v2.57","doi-asserted-by":"publisher","DOI":"10.1042\/cs20240833"},{"key":"2026060603451896000_2026.02.26.708088v2.58","doi-asserted-by":"crossref","unstructured":"Jia G , Mantzoros CS , Hill MA . Inter-organ crosstalk in health and cardiovascular-renal-hepatic-metabolic disease: A multidisciplinary perspective. Metabolism. 2026;174:156424.","DOI":"10.1016\/j.metabol.2025.156424"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.26.708088","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T10:45:32Z","timestamp":1780742732000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.26.708088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,28]]},"references-count":58,"URL":"https:\/\/doi.org\/10.64898\/2026.02.26.708088","relation":{},"subject":[],"published":{"date-parts":[[2026,2,28]]},"subtype":"preprint"}}